| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 77.2 | 100.1 | 84.1 |
| Other income | 1.6 | -3.0 | 2.3 |
| Total income | 78.9 | 97.1 | 86.4 |
| Profit before exceptional items & tax | 16.3 | 22.2 | 20.2 |
| Exceptional items | 85.3 | 2.9 | 0.0 |
| Profit before tax | 101.7 | 25.1 | 20.2 |
| Net profit | 96.7 | 16.5 | 17.3 |
| Operating margin | 128.9% | 25.8% | 23.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +459.00% |
|---|---|
| Net profit, quarter on quarter | +486.10% |
| Revenue, year on year | -8.20% |
| Operating profit, year on year | +534.00% |
| Operating profit, quarter on quarter | +387.70% |
BSE results filing, NSE: HESTERBIO. Figures extracted from the filing.
Hester Biosciences Ltd: key numbers
- Share price
- ₹2,182.90
- Market cap
- ₹1,857 Cr
- Revenue (annual)
- ₹332.6 Cr
- Net profit (annual)
- ₹55.64 Cr
- P/E (TTM)
- 13.6×Sector 50.4×
- Promoter holding
- 53.73%+0.00% QoQ
- FII holding
- 0.31%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hester Biosciences Ltd
All →Hester Biosciences Promoter Reclassification
Hester Biosciences Limited received shareholder approval to reclassify Mr. Ravin Gandhi and Ms. Bela Gandhi from the 'Promoter' category to the 'Public' category.
Hester Biosciences Annual General Meeting
Hester Biosciences Limited shareholders approved the reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from 'Promoter' to 'Public' category via postal ballot.
Hester Biosciences Earnings Call Transcript: Key Takeaways
Hester Biosciences delivered strong standalone Q1 growth with revenues up 14% and profit up 88%. Consolidated profit surged 459% due to an INR 853.49 million exceptional gain from a loan amendment.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences reported Q4 and FY26 results with consolidated revenue growth of 22% and substantial PAT increase. Strategy focuses on biologicals, capacity utilization, and African market expansion.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences reported FY26 consolidated revenue of ₹3,325.99 Mn (₹332.60 Cr) and PAT of ₹57.48 Cr, focusing on global expansion in animal and poultry vaccines.
Hester Biosciences Earnings Call: Key Takeaways
Hester Biosciences delivered a strong Q3 FY26 with standalone revenue up 12% and PAT up 140%, driven by robust Poultry Healthcare performance and operational leverage despite Animal Healthcare headwinds.